WO2000034308A3 - Protein transduction system and methods of use thereof - Google Patents

Protein transduction system and methods of use thereof Download PDF

Info

Publication number
WO2000034308A3
WO2000034308A3 PCT/US1999/029289 US9929289W WO0034308A3 WO 2000034308 A3 WO2000034308 A3 WO 2000034308A3 US 9929289 W US9929289 W US 9929289W WO 0034308 A3 WO0034308 A3 WO 0034308A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein transduction
transduction system
domain
transduction
methods
Prior art date
Application number
PCT/US1999/029289
Other languages
French (fr)
Other versions
WO2000034308A2 (en
Inventor
Steven F Dowdy
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Priority to CA002354044A priority Critical patent/CA2354044A1/en
Priority to JP2000586751A priority patent/JP2002531113A/en
Priority to EP99966101A priority patent/EP1137664A2/en
Priority to AU21728/00A priority patent/AU2172800A/en
Publication of WO2000034308A2 publication Critical patent/WO2000034308A2/en
Publication of WO2000034308A3 publication Critical patent/WO2000034308A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a protein transduction system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated in a cell exhibiting a unique characteristic. Further provided are protein transduction domains that provide enhanced transduction efficiency. The protein transduction system effectively kills or injures cells infected by one or a combination of different pathogens or cells exhibiting unique characteristics such as high levels of heavy metals, DNA damage or uncontrolled cell division.
PCT/US1999/029289 1998-12-10 1999-12-10 Protein transduction system and methods of use thereof WO2000034308A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002354044A CA2354044A1 (en) 1998-12-10 1999-12-10 Protein transduction system and methods of use thereof
JP2000586751A JP2002531113A (en) 1998-12-10 1999-12-10 Protein transduction system and methods of use
EP99966101A EP1137664A2 (en) 1998-12-10 1999-12-10 Protein transduction system and methods of use thereof
AU21728/00A AU2172800A (en) 1998-12-10 1999-12-10 Protein transduction system and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11170198P 1998-12-10 1998-12-10
US60/111,701 1998-12-10

Publications (2)

Publication Number Publication Date
WO2000034308A2 WO2000034308A2 (en) 2000-06-15
WO2000034308A3 true WO2000034308A3 (en) 2000-10-19

Family

ID=22340003

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/029289 WO2000034308A2 (en) 1998-12-10 1999-12-10 Protein transduction system and methods of use thereof

Country Status (5)

Country Link
EP (1) EP1137664A2 (en)
JP (1) JP2002531113A (en)
AU (1) AU2172800A (en)
CA (1) CA2354044A1 (en)
WO (1) WO2000034308A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8974774B2 (en) 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
JP5610659B2 (en) 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Multi-component biological transport system
US20020142299A1 (en) * 2001-01-09 2002-10-03 Davidson Beverly L. PTD-modified proteins
AU2002322009A1 (en) * 2001-05-18 2002-12-03 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US20030083262A1 (en) * 2001-08-30 2003-05-01 Praecis Pharmaceuticals Inc. Methods and compositions for treating inflammatory disorders
WO2003097671A1 (en) 2002-03-29 2003-11-27 Creagene Inc. Cytoplasmic transduction peptides and uses thereof
AU2003229335A1 (en) * 2002-05-17 2003-12-02 Washington University Compositions and methods for treatment of wounds
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
BRPI0411485A (en) * 2003-06-30 2006-07-25 Univ Lausanne rasgap-derived peptide to selectively kill cancer cells
EP2133362B1 (en) 2003-07-25 2012-04-18 Amgen, Inc Methods relating to LDCAM and CRTAM
WO2005122675A2 (en) * 2004-06-21 2005-12-29 Quattromed As Optimized recognition site of the alphavirus non-structural protease for tag removal and specific processing of recombinant proetins
EP2801366A3 (en) * 2004-09-02 2015-04-29 Cognosci, Inc. Improved apo E analogs and methods for their use
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
BRPI0608091A2 (en) 2005-03-03 2009-11-10 Revance Therapeutics Inc compositions and processes for topical application and transdermal delivery of an oligopeptide
AU2006340711C1 (en) 2005-04-05 2013-02-07 Allergan, Inc. Clostridial toxin activity assays
NZ582459A (en) 2007-07-26 2012-05-25 Revance Therapeutics Inc Antimicrobial peptide, compositions, and methods of use
AU2009223161B2 (en) 2008-03-14 2014-10-30 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
PT2406371T (en) 2009-03-13 2018-10-18 Allergan Inc Cells useful for immuno-based botulinum toxin serotype a activity assays
DK3281953T3 (en) 2009-03-13 2020-01-20 Allergan Inc IMMUN-BASED REDIRECT ENDOPEPTIDASE ACTIVITY ASSAYS
EP2488210A4 (en) 2009-10-12 2014-04-30 Smith Holdings Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
EP2627674A4 (en) * 2010-10-12 2014-04-30 Arizona Biomedical Res Commission Egfr-based peptides
US9096886B2 (en) * 2011-03-11 2015-08-04 Merz Pharma Gmbh & Co. Kgaa Method for the determination of botulinum neurotoxin biological activity
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US10078085B2 (en) 2012-08-22 2018-09-18 Mogam Biothechnology Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
MX370929B (en) 2012-10-28 2020-01-08 Revance Therapeutics Inc Compositions and methods for safe treatment of rhinitis.
US9724378B2 (en) 2014-05-19 2017-08-08 Samsung Electronics Co., Ltd. Fusion protein comprising granzyme B and use thereof
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2016161440A2 (en) 2015-04-03 2016-10-06 Arizona Cancer Therapeutics, Llc Egfr-based inhibitor peptides for combinatorial inactivation of erbb1, erbb2, and erbb3

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0609580A1 (en) * 1988-01-29 1994-08-10 Chiron Corporation Recombinant CMV neutralising proteins
EP0610046A2 (en) * 1993-02-01 1994-08-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispesific fusion proteins in a mammalian cell
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
WO1999055899A1 (en) * 1998-04-28 1999-11-04 Washington University Methods for transducing fusion molecules

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0609580A1 (en) * 1988-01-29 1994-08-10 Chiron Corporation Recombinant CMV neutralising proteins
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
EP0610046A2 (en) * 1993-02-01 1994-08-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispesific fusion proteins in a mammalian cell
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
WO1999055899A1 (en) * 1998-04-28 1999-11-04 Washington University Methods for transducing fusion molecules

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BONIFACI N. ET AL.: "Nuclear Translocation of an Exogenous Fusion Protein Containing HIV Tat Requires Unfolding", AIDS,, vol. 9, no. 9, 1995, pages 995 - 1000, XP002927983 *
CHEN L.L. ET AL.: "Increased Cellular Uptake of the Human Immunodeficiency Virus-1 tat Protein After Modification with Biotin", ANALYTICAL BIOCHEMISTRA,, vol. 227, 1995, pages 168 - 175, XP002927982 *
GREEN ET AL.: "mutational Amalysis of HIV-1 tat Minimal Domain Peptides: Identification of Trans-Dominant Mutants That Suppress HIV-LTR-Driven Gene Expression", CELL,, vol. 58, 1989, pages 215 - 223, XP002927984 *
KOLESNITCHENKO V. ET AL.: "A Major Human Immunodeficiency Virus Type 1-Initiated Killing Pathway Distinct from Apoptosis", JOURNAL OF VIROLOGY,, vol. 71, no. 12, December 1997 (1997-12-01), pages 9753 - 9763, XP002927985 *
MOCHIZUKI ET AL.: "High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells", JOURNAL OF VIROLOGY,, vol. 72, no. 11, November 1998 (1998-11-01), pages 8873 - 8883, XP002927986 *
NAGAHARA ET AL.: "Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27kip1 induces cell migration", NATURE MEDICINE,, vol. 4, no. 12, December 1998 (1998-12-01), pages 1449 - 1452, XP002927987 *
SCHARZE ET AL.: "In vivo protein transduction: Delivery of a biologically active protein into the mouse", SCIENCE,, vol. 285, no. 5433, 3 September 1999 (1999-09-03), pages 1569 - 1572, XP002927988 *
TALANIAN R.V. ET AL.: "Granule-Mediated Killing: Pathways for Granzyme B-initiated Apoptosis", J. EXP. MED.,, vol. 186, no. 8, 20 October 1997 (1997-10-20), pages 1323 - 1331, XP002927981 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8974774B2 (en) 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9180081B2 (en) 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9314416B2 (en) 2005-03-03 2016-04-19 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins

Also Published As

Publication number Publication date
WO2000034308A2 (en) 2000-06-15
EP1137664A2 (en) 2001-10-04
AU2172800A (en) 2000-06-26
CA2354044A1 (en) 2000-06-15
JP2002531113A (en) 2002-09-24

Similar Documents

Publication Publication Date Title
WO2000034308A3 (en) Protein transduction system and methods of use thereof
EP1322307A4 (en) Methods for treating cell proliferative disorders and viral infections
NZ316787A (en) Methods and compositions for the selective modification of nucleic acids
WO2004063362A3 (en) Cell cycle progression proteins
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
CA2335153A1 (en) Enzyme stabilization by cationic surfactants
CA2274581A1 (en) Oligonucleotide compositions and methods for the modulation of the expression of b7 protein
AU6355396A (en) New cationic and polycationic amphiphiles, reactives containing the same and their use
AU3370700A (en) Modified lithium vanadium oxide electrode materials, products, and methods
WO2000018914A3 (en) Novel dkr polypeptides
WO2001080840A3 (en) Cytotoxic agents comprising single-stranded and/or looped dna
EP1967590A3 (en) Lentiviral packaging constructs
AU3262797A (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
EP1131332A4 (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
WO1999004011A3 (en) Hiv-1 group o antigens and uses thereof
CA2336261A1 (en) Cyclin e2 genes and proteins
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses
DE60039679D1 (en) REDUCTION OF THE MOLECULAR WEIGHT OF OLEFIN COPOLYMERISATES
IT1293978B1 (en) FERMENTATION TANK, PARTICULARLY FOR THE RED VINIFICATION.
AU2003216273A1 (en) Pseudomonas avr and hop proteins, their encoding nucleic acids, and use thereof
AU9269898A (en) Artificial viruses derived from papillomavirus, and their uses, in particular gene therapy
BR9914722A (en) Anticonvulsant derivatives useful in the treatment of alcohol dependence, addiction and abuse
WO2001058954A3 (en) Trade molecules and uses related thereto
WO2002017900A9 (en) Modulators of us28 (chemokines) for treating cytomegalovirus infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2354044

Country of ref document: CA

Ref country code: CA

Ref document number: 2354044

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 586751

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 21728/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999966101

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999966101

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999966101

Country of ref document: EP